Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Add-on Therapies

Home Medications Add-on Therapies

Add-on Therapy Symptom Control

Add-on therapies can be considered to improve symptom control or as a dose-reduction strategy to limit the side effects of primary therapies (e.g. high-dose corticosteroids or long-term oral corticosteroids). The biological processes underlying asthma are heterogeneous, so detailed characterisation of the individual patient phenotype and an individual risk/benefit assessment should be undertaken before proceeding with add-on therapies. For more information see Phenotypes & Phenotyping.

These can be trialled in individual patients by comparing symptom control before and after treatment for a defined period, at a time when nothing else is being changed (modified “n of 1 trials”). There is little point in continuing add-on therapies long term if there is no obvious improvement.

Monoclonal antibodies (biologicals)
Long Acting Muscarinic Antagonists (LAMAs)
Leukotriene Receptor Antagonists (LTRAs)
Anti-fungal (Itraconazole)
Theophylline
Immunosuppressive therapy
Macrolide Antibiotics
Monoclonal antibodies (biologicals)

Increasingly emerging as targeted therapies that block specific molecular pathways in severe asthma. Monoclonal antibodies work by binding to and blocking the function of a specific target molecule. Monoclonal antibody treatments are also expensive. As such, patient phenotyping and targeted use of biologicals in severe asthma is critical. An individual will only respond to a particular treatment, if that specific molecule / pathway underlies their disease.

Monoclonal Antibody for add-on therapy
Long Acting Muscarinic Antagonists (LAMAs)

Promote bronchodilation and increase airflow. Increasing evidence suggests that tiotropium can reduce exacerbation risk and improve lung function in severe asthma in those with an FEV1 less than 80% predicted. In Australia, tiotropium by mist inhaler is PBS-listed as an add-on treatment to ICS and LABA in severe asthma, in patients who have experienced ≥1 severe exacerbation in the previous year.

Leukotriene Receptor Antagonists (LTRAs)

Some evidence supports the use of LTRAs as an add-on to ICS in moderate asthma and aspirin-exacerbated respiratory disease (previously called aspirin-sensitive asthma). However, no data are yet available for severe asthma, and there is no data to support long term use of LTRAs in the absence of a clear symptomatic improvement.

Anti-fungal (Itraconazole)

Fungal sensitisation is common in severe asthma, and should be tested for in individual patients, by quantifying the presence of IgE antibodies against specific fungi. Anti-fungal treatment (itraconazole) may be useful in some patients that have demonstrated high sensitisation to individual fungi or who have recurrent exacerbations of allergic bronchopulmonary aspergillosis (ABPA). However, the risk of clinically important adrenal suppression due to interactions with inhaled corticosteroids and other medications must be taken into account. These recommendations apply only to the use of anti-fungal agents for the treatment of asthma, and do not refer to the treatment of other indications (e.g. fungal infections).

Theophylline

Can be used as an add-on therapy. However, LABAs have been demonstrated to be more effective and very limited data exists for the use of theophylline in severe asthma. Further, side-effects are an important consideration.

Immunosuppressive therapy

Immunosuppressive interventions have been proposed as a “corticosteroid-sparing” strategy. However, marginal benefits have been demonstrated in patients. The ATS/ERS guidelines recommended against the use of methotrexate in adults or children with severe asthma. This was a conditional recommendation, based on low quality evidence, which highlighted the limited benefits of treatment and the potential for adverse events (Chung et al. 2014). Due to negative side effects, their risk/benefit requires careful consideration.

Macrolide Antibiotics

Macrolide antibiotics (e.g. azithromycin) have both immunomodulatory and anti-inflammatory effects that may be of benefit in severe asthma. Benefit has been demonstrated in other inflammatory lung diseases, including cystic fibrosis, bronchiectasis and COPD. A recent clinical trial of individuals with persistent uncontrolled asthma provided evidence that azithromycin treatment for 48-weeks reduced exacerbations and improved quality of life (Gibson et al. 2017). People with prolonged QT interval on ECG, and those with hearing impairment, were excluded from this trial. The potential for bacterial antibiotic resistance with widespread use remains a concern. Ongoing research is examining the most appropriate way to use macrolides in severe asthma. A presentation on macrolide use in asthma is available here.

For more information see Azithromycin Clinic Recommendations.

Macrolide
Click here to download a printable version of the “Azithromycin Treatment for Severe Asthma” infographic

Access the full suite of infographics here.

Additional Resources:

  • Inflammation Biomarkers in the Assessment and Management of Severe Asthma – Tools and Interpretation: This document provides an overview of fractional exhaled nitric oxide (FeNO) and eosinophil numbers as biomarkers to inform asthma management, including assessment approaches and interpretation of findings.
Previous
Next

Last Updated on November 7, 2019

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Overview
  • Relievers
  • Preventers / Controllers
  • Add-on Therapies
  • Monoclonal Antibodies
  • Bronchial Thermoplasty
For considerations relevant to the paediatric and adolescent population, please see Medications in Paediatrics

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia